The Global Acetazolamide Market, by Formulation (Tablets, Capsules, and Injection), by Application (Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention, Heart Failure, and Seizures), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 191.8 million in 2018, and is projected to exhibit a CAGR of 4.8% during the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
Acetazolamide is one of the most preferred medication for glaucoma incidences as it helps in relieving symptoms and reduces risk of serious complications among patients of glaucoma. Acetazolamide is sold under different trade names including AZM, Diamox, Acemox, Evamox, and Setacar. The drug is used to treat glaucoma, epilepsy, attitude sickness, and heart failure induced edema.
Browse 23 Market Data Tables and 25 Figures spread through 152 Pages and in-depth TOC on "Acetazolamide Market, by Formulation (Tablets, Capsules and Injection), by Application (Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention, Heart Failure and Seizures), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to acetazolamide market, click the link below:
Furthermore, key players are engaged in launching acetazolamide-based products along with gaining regulatory approval for the same in the market.
For instance, in November 2017, Strides Pharma Global Pte. Ltd. — subsidiary of Strides Shasun Limited—received approval from the U.S. Food and Drug Administration (FDA) for acetazolamide tablets, 125 mg and 250 mg, a generic version of Diamox Tablets. Acetazolamide tablet is used to prevent and reduce the symptoms of altitude sickness and treat a certain type of eye problem (open-angle glaucoma). In the U.S., company’s acetazolamide tablets are marketed by Strides Pharma Inc.
Furthermore, in November 2012, Sagent Pharmaceuticals introduced acetazolamide for injection, specified for adjunctive treatment of edema due to congestive heart failure, drug-induced edema, centrencephalic epilepsies, and chronic simple glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma.
Key takeaways of the Acetazolamide Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.